{"organizations": [], "uuid": "ebb18ce6595f8deb778b444ae59601af15655ecf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-neurocrine-will-file-nda-for-opica/brief-neurocrine-will-file-nda-for-opicapone-for-parkinsons-disease-based-on-existing-pivotal-clinical-trial-data-idUSASB0C5R6", "country": "US", "domain_rank": 408, "title": "BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.35, "site_type": "news", "published": "2018-02-15T05:12:00.000+02:00", "replies_count": 0, "uuid": "ebb18ce6595f8deb778b444ae59601af15655ecf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neurocrine-will-file-nda-for-opica/brief-neurocrine-will-file-nda-for-opicapone-for-parkinsons-disease-based-on-existing-pivotal-clinical-trial-data-idUSASB0C5R6", "ord_in_thread": 0, "title": "BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "neurocrine biosciences inc", "sentiment": "negative"}, {"name": "neurocrine biosciences", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "parkinson", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "neurocrine", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 14, 2018 / 9:12 PM / Updated 7 minutes ago BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data Reuters Staff 1 Min Read Feb 14 (Reuters) - Neurocrine Biosciences Inc: * NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSONâ€˜S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA * NEUROCRINE BIOSCIENCES INC - NEUROCRINE WILL PROCEED WITH PLANS TO FILE NDA FOR OPICAPONE DURING FIRST HALF OF 2019 * NEUROCRINE BIOSCIENCES INC - U.S. FDA HAS PROVIDED GUIDANCE ON REGULATORY PATH FORWARD TO SUPPORT NDA FOR OPICAPONE * NEUROCRINE BIOSCIENCES INC - NEUROLOGY DIVISION OF FDA HAS NOT REQUESTED CO TO CONDUCT AN ADDITIONAL PHASE III STUDY FOR OPICAPONE PRIOR TO NDA FILING Source text for Eikon: Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T05:12:00.000+02:00", "crawled": "2018-02-14T23:26:11.068+02:00", "highlightTitle": ""}